Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rekovelle for Intrauterine Successful Experience (RISE)
2025-520681-22-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of recombinant human follicle stimulating hormone in female infertility, sponsored by Centre Hospitalier Intercommunal de Créteil. Primary endpoint: Two mature follicles without intermediate follicles per cycle at trigger. Planned start Jul 2025; status: authorised.
02
Drugs
recombinant human follicle stimulating hormone
03
Conditions
female infertility
Beyond the preview
Go deeper on 2025-520681-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520681-22-00.